Arkolith/Insider Trading/DFFN/Form 4

Lanchoney Diana M

DirectorDiffusion Pharmaceuticals Inc. (DFFN) · full profile →Form 4 · filed Apr 3, 2023
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
3
2 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Mar 31, 2023Disposed to issuer(D)85——147
Mar 31, 2023Option exercise(M)232——232

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Mar 31, 2023Option exercise(M)232—$01K

Transaction Codes

D
Disposition to the issuer
M
Option exercise / conversion

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001437749-23-009126) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML